Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

QR Code

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

Bibliographic Details
Main Authors:	Chan, Arlene, Miles, D., Pivot, X.
Format:	Journal Article
Published:	Oxford University Press 2010
Online Access:	http://hdl.handle.net/20.500.11937/7623

Similar Items

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
by: Gianni, L., et al.
Published: (2013)

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2010)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
by: Cinieri, S., et al.
Published: (2017)

Capecitabine and vinorelbine in metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2009)

TILs in metastatic breast cancer—no surprises, but more questions
by: Chan, Arlene
Published: (2017)

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
by: Dent, R., et al.
Published: (2013)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer
by: Chan, Arlene, et al.
Published: (2012)

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase 11 study
by: Hyams, D., et al.
Published: (2013)

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
by: Cameron, David, et al.
Published: (2013)

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study
by: Bergh, J., et al.
Published: (2012)

Randomized Phase 111 Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endrocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
by: Wolff, A., et al.
Published: (2013)

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
by: Wolff, A., et al.
Published: (2013)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
by: De Boer, R., et al.
Published: (2012)

Pigment epithelium-derived factor and menopause in metastatic breast cancer
by: Brook, Naomi Louise
Published: (2022)

Glutamate regulation of Voltage-Gated Sodium Channels (VGSCS) in breast cancer cell lines of different metastatic potential
by: Azahar, Irfan Irsyad
Published: (2022)

Studies towards low oxidation state taxanes
by: Sadia, Reema
Published: (2022)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)

Evaluation of fatty liver in breast cancer patients and its metastatic potential
by: Ahmad, Nor Hayati
Published: (2021)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan, Arlene, et al.
Published: (2012)

Role of novel therapeutic agents in modulating invadopodia formation in metastatic breast cancer
by: Siti Nor Aini Harun,, et al.
Published: (2020)

DEAD-box helicase DP103 defines metastatic potential of human breast cancers
by: Shin, E., et al.
Published: (2014)

An investigation of metastatic colorectal cancer
by: Asiri, Abutaleb
Published: (2018)

Trastuzumab biosimilar in early breast cancer setting: Will there be direct patient benefits?
by: Chan, Arlene
Published: (2017)

Treatment of MCF-7 and MDA-MB-231 human breast cancer cell lines with erythropoietin, doxorubicin and their combination
by: Radwan, Esam M.
Published: (2015)

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

Synthetic chemistry and synthetic biology approaches to low oxidation state taxanes
by: Marsh, Benjamin J.
Published: (2017)

Understanding factors associated with delay in seeking treatment among locally advanced and metastatic breast cancer in Hospital Raja Perempuan Zainab II
by: Karim, Mohd Firdaus A.
Published: (2020)

Investigation of Taxol biosynthetic genes for the production of novel taxanes in heterologous plant systems
by: Narraidoo, Nathalie
Published: (2011)

Investigating the role of Cten in metastatic colorectal cancer
by: Thorpe, Hannah
Published: (2016)

The study of relationship between cancer markers and age of patient in primary and metastatic paraffinized breast cancer tissue / Nur Azimah Osman
by: Osman, Nur Azimah
Published: (2009)

Microbiota profile of Malaysian kefir grain and anti-metastatic effects of kefir water in murine breast cancer cells
by: Zamberi, Nur Rizi
Published: (2016)

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer
by: Alexander, Angela, et al.
Published: (2017)

Cytotoxic effects of damnacanthal and damnacanthal-doxorubicin combination on human breast cancer cell line (MCF-7)
by: Abdul Aziz, Muhammad Yusran
Published: (2012)

Investigation the role of CD24 in metastatic colorectal cancer
by: Alsulaiman, Abdullah
Published: (2018)

Molecular characterisation of the early metastatic phenotype in colorectal cancer
by: Sculthorpe, Declan
Published: (2024)

The current status of checkpoint inhibitors in metastatic bladder cancer
by: Fahmy Ahmed, Omar Ahmed, et al.
Published: (2016)

Optimising targeted antibodies for the treatment of metastatic solid tumours
by: Herbertson, Rebecca A.
Published: (2009)